Park, Soon Young http://orcid.org/0000-0001-6594-6364
Jeong, Kang Jin
Poire, Alfonso http://orcid.org/0000-0001-8026-1689
Zhang, Dong
Tsang, Yiu Huen http://orcid.org/0000-0002-0895-6854
Blucher, Aurora S.
Mills, Gordon B. http://orcid.org/0000-0002-0144-9614
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (UO1 CA253472, U01 CA217842)
Breast Cancer Research Foundation ((BCRF)-22-101)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 30 January 2023
Revised: 29 July 2023
Accepted: 4 August 2023
First Online: 18 August 2023
Competing interests
: GBM is a SAB member or Consultant: for Amphista, Astex, AstraZeneca, BlueDot, Chrysallis Biotechnology, Ellipses Pharma, GSK, ImmunoMET, Infinity, Ionis, Leapfrog Bio, Lilly, Medacorp, Nanostring, Nuvectis, PDX Pharmaceuticals, Qureator, Roche, Signalchem Lifesciences, Tarveda, Turbine, Zentalis Pharmaceuticals. GBM has Stock/Options/Financial relationships with: Bluedot, Catena Pharmaceuticals, ImmunoMet, Nuvectis, SignalChem, Tarveda, and Turbine. GBM has Licensed Technology: HRD assay to Myriad Genetics, DSP patents with Nanostring. GBM has Sponsored research with AstraZeneca.
: Ethics approval and adherence to ethical guidelines were obtained for the animal protocols used in this research study, as reviewed and approved by the Institutional Animal Care and Use Committee (IACUC, TR01_IP00002062).